OBJECTIVE: This study investigated the schizophrenia phenotype in 24 subjects with 22q11 deletion syndrome (22qDS) and schizophrenia (22qDS-schizophrenia), a rare but relatively homogenous genetic subtype of schizophrenia associated with a microdeletion on chromosome 22. Individuals with 22qDS are at genetically high risk for schizophrenia. METHOD: Standard measures of signs, symptoms, and course of schizophrenia were assessed in 16 adults with 22qDS-schizophrenia who did not meet criteria for mental retardation and in 46 adults with schizophrenia without evidence of 22qDS from a community familial sample. RESULTS: There were no significant differences in age at onset, lifetime or cross-sectional core positive and negative schizophrenic symptoms, or global functioning between the two groups of patients with schizophrenia. Patients with 22qDS-schizophrenia had higher excitement subscale scores and less lifetime substance use than the comparison patients with schizophrenia, but no significant differences in anxiety-depression symptom severity were found between the groups. CONCLUSIONS: These findings indicate that the core clinical schizophrenia phenotype would not distinguish individuals with a 22qDS subtype from those with schizophrenia who did not have the 22qDS subtype. The results provide further support for the utility of 22qDS-schizophrenia as a neurodevelopmental model of schizophrenia as well as support for prospective studies of individuals with 22qDS to help identify precursors of schizophrenia.
OBJECTIVE: This study investigated the schizophrenia phenotype in 24 subjects with 22q11 deletion syndrome (22qDS) and schizophrenia (22qDS-schizophrenia), a rare but relatively homogenous genetic subtype of schizophrenia associated with a microdeletion on chromosome 22. Individuals with 22qDS are at genetically high risk for schizophrenia. METHOD: Standard measures of signs, symptoms, and course of schizophrenia were assessed in 16 adults with 22qDS-schizophrenia who did not meet criteria for mental retardation and in 46 adults with schizophrenia without evidence of 22qDS from a community familial sample. RESULTS: There were no significant differences in age at onset, lifetime or cross-sectional core positive and negative schizophrenic symptoms, or global functioning between the two groups of patients with schizophrenia. Patients with 22qDS-schizophrenia had higher excitement subscale scores and less lifetime substance use than the comparison patients with schizophrenia, but no significant differences in anxiety-depression symptom severity were found between the groups. CONCLUSIONS: These findings indicate that the core clinical schizophrenia phenotype would not distinguish individuals with a 22qDS subtype from those with schizophrenia who did not have the 22qDS subtype. The results provide further support for the utility of 22qDS-schizophrenia as a neurodevelopmental model of schizophrenia as well as support for prospective studies of individuals with 22qDS to help identify precursors of schizophrenia.
Authors: A I Green; M Tohen; J K Patel; M Banov; C DuRand; I Berman; H Chang; C Zarate; J Posener; H Lee; R Dawson; C Richards; J O Cole; A F Schatzberg Journal: Am J Psychiatry Date: 2000-06 Impact factor: 18.112
Authors: R Nicolson; J N Giedd; M Lenane; S Hamburger; S Singaracharlu; J Bedwell; T Fernandez; G K Thaker; D Malaspina; J L Rapoport Journal: Am J Psychiatry Date: 1999-10 Impact factor: 18.112
Authors: D Gothelf; A Frisch; H Munitz; R Rockah; N Laufer; T Mozes; H Hermesh; A Weizman; M Frydman Journal: Schizophr Res Date: 1999-01-11 Impact factor: 4.939
Authors: Liam J Drew; Gregg W Crabtree; Sander Markx; Kimberly L Stark; Florence Chaverneff; Bin Xu; Jun Mukai; Karine Fenelon; Pei-Ken Hsu; Joseph A Gogos; Maria Karayiorgou Journal: Int J Dev Neurosci Date: 2010-10-08 Impact factor: 2.457
Authors: Karine Fénelon; Bin Xu; Cora S Lai; Jun Mukai; Sander Markx; Kimberly L Stark; Pei-Ken Hsu; Wen-Biao Gan; Gerald D Fischbach; Amy B MacDermott; Maria Karayiorgou; Joseph A Gogos Journal: J Neurosci Date: 2013-09-11 Impact factor: 6.167
Authors: Jeffrey D Zaremba; Anastasia Diamantopoulou; Nathan B Danielson; Andres D Grosmark; Patrick W Kaifosh; John C Bowler; Zhenrui Liao; Fraser T Sparks; Joseph A Gogos; Attila Losonczy Journal: Nat Neurosci Date: 2017-09-04 Impact factor: 24.884